The clinical trial with ibrutinib, a dual inhibitor against bruton tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK), has shown the improvement of T cell number and T cell function in CLL patients treated with ibrutinib for more than one year [271]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.